BioNTech (NASDAQ:BNTX) Sees Unusually-High Trading Volume – Time to Buy?

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) saw unusually-high trading volume on Thursday . Approximately 774,507 shares traded hands during mid-day trading, a decline of 27% from the previous session’s volume of 1,066,491 shares.The stock last traded at $109.69 and had previously closed at $113.12.

BioNTech News Roundup

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: BioNTech highlighted continued momentum in its late-stage lung-cancer program and plans to present new clinical data at the IASLC 2026 World Conference on Lung Cancer. The company will also report the first global data for the pumitamig/elfetabart drozuntecan combination, giving investors a potential catalyst for its non-COVID oncology strategy. BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data
• Neutral Sentiment: BioNTech’s earlier rally followed positive topline data from Moderna and Merck involving individualized cancer therapy for advanced skin cancer. The reaction reflects investor interest in the broader cancer-vaccine opportunity, but Moderna’s results do not directly establish the efficacy of BioNTech’s programs. Why Is BioNTech Stock Surging on Wednesday?
• Negative Sentiment: Moderna’s sharp reversal after its prior surge is weighing on related cancer-vaccine stocks, including BioNTech. The move suggests investors are locking in gains and questioning whether the sector’s initial enthusiasm was excessive. Moderna Sinks After Cancer Vaccine Rally
• Negative Sentiment: Leerink analysts cautioned that BioNTech’s rally based on Moderna’s trial success may fade, reinforcing concerns that the stock’s recent gains were driven more by sector sentiment than company-specific clinical results. BioNTech’s Rally on Moderna Trial Win Likely to Fade

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Canaccord Genuity Group set a $142.00 price objective on BioNTech in a research note on Wednesday, August 5th. Wall Street Zen downgraded BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Berenberg Bank reduced their price target on BioNTech from $155.00 to $140.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. HC Wainwright reaffirmed a “buy” rating and issued a $130.00 price objective on shares of BioNTech in a research note on Monday, April 27th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of BioNTech in a research report on Friday, June 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $127.81.

BioNTech Stock Down 1.5%

The stock has a market capitalization of $28.19 billion, a P/E ratio of -14.24 and a beta of 1.27. The company’s 50-day moving average price is $92.48 and its 200 day moving average price is $95.66. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85.

BioNTech (NASDAQ:BNTX) last released its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The firm had revenue of $122.31 million for the quarter, compared to analysts’ expectations of $180.18 million. During the same quarter last year, the firm posted ($1.60) EPS. The firm’s quarterly revenue was down 59.5% compared to the same quarter last year. As a group, equities analysts expect that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current year.

BioNTech announced that its board has approved a share buyback plan on Thursday, May 7th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the company to purchase up to 4.2% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

Hedge Funds Weigh In On BioNTech

A number of hedge funds have recently made changes to their positions in the business. Flossbach Von Storch SE purchased a new position in BioNTech in the 2nd quarter worth approximately $207,142,000. GSK plc bought a new position in BioNTech in the 4th quarter worth approximately $84,711,000. BNP Paribas Financial Markets grew its holdings in BioNTech by 43.0% during the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after buying an additional 474,796 shares in the last quarter. First Trust Advisors LP grew its holdings in BioNTech by 116.0% during the 1st quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock valued at $74,658,000 after buying an additional 451,124 shares in the last quarter. Finally, Bank of America Corp DE raised its position in shares of BioNTech by 344.4% during the third quarter. Bank of America Corp DE now owns 573,356 shares of the company’s stock valued at $56,544,000 after buying an additional 444,332 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.